Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6534
    +0.0010 (+0.16%)
     

  • OIL

    83.65
    +0.08 (+0.10%)
     

  • GOLD

    2,349.50
    +7.00 (+0.30%)
     

  • Bitcoin AUD

    97,644.62
    -1,204.83 (-1.22%)
     

  • CMC Crypto 200

    1,331.33
    -65.20 (-4.67%)
     

  • AUD/EUR

    0.6105
    +0.0032 (+0.53%)
     

  • AUD/NZD

    1.0992
    +0.0035 (+0.32%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,733.69
    +303.19 (+1.74%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • Dow Jones

    38,251.84
    +166.04 (+0.44%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

COVAXX gets supply deals worth $2.8 bln for potential COVID-19 vaccine

Reuters
·1-min read

Nov 25 (Reuters) - COVAXX, a unit of United Biomedical Inc, said on Thursday it has received purchase commitments totaling $2.8 billion to deliver more than 140 million doses of its potential COVID-19 vaccine to developing countries, including Brazil, Peru and Ecuador.

The multitope peptide-based vaccine is currently in early-stage trials in Taiwan, lagging some of the frontrunners in the race to develop a safe and effective vaccine.

The U.S.-based company signed an agreement in September with Brazilian lab and hospital group DASA S.A. to conduct mid-to-late stage trials in Brazil for the vaccine.

COVAXX estimates it can produce 100 million doses in first half of next year and 1 billion by end of 2021.

Last month, the company signed a logistics partnership with Maersk for transportation and supply chain services that will be needed to deliver the vaccine around the world. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)